Treatment of pulmonary fibrosis in systemic sclerosis: Light at the end of the tunnel?
Open Access
- 1 January 2006
- journal article
- editorial
- Published by Wiley in Arthritis & Rheumatism
- Vol. 56 (1) , 9-12
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosisArthritis & Rheumatism, 2007
- Imatinib mesylate inhibits platelet derived growth factor stimulated proliferation of rheumatoid synovial fibroblastsBiochemical and Biophysical Research Communications, 2006
- Imatinib mesylate inhibits proliferation of rheumatoid synovial fibroblast-like cells and phosphorylation of Gab adapter proteins activated by platelet-derived growth factorClinical and Experimental Immunology, 2006
- Mechanisms and consequences of fibrosis in systemic sclerosisNature Clinical Practice Rheumatology, 2006
- Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung diseaseRheumatology, 2006
- Amelioration of autoimmune nephritis by imatinib in MRL/lpr miceArthritis & Rheumatism, 2005
- Reversal of experimental pulmonary hypertension by PDGF inhibitionJournal of Clinical Investigation, 2005
- Regulation of PDGF and its receptors in fibrotic diseasesCytokine & Growth Factor Reviews, 2004
- Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemiaClinical Rheumatology, 2003
- Expression of platelet-derived growth factor B-chain and platelet-derived growth factor β-receptor in fibroblasts of sclerodermaJournal of Dermatological Science, 1998